Drug intelligence / Profile preview

Saypha CHIC

Development stage: Preclinical
Lead developer: Croma-Pharma
Modality: Recombinant Proteins and Enzymes
Administration: Subcutaneous, Intradermal

Overview

Saypha CHIC is a branded hyaluronic acid dermal filler from Croma-Pharma’s saypha portfolio, licensed to Obagi Medical/Waldencast for the U.S. market as Obagi saypha ChIQ. It is an injectable, crosslinked, non-animal hyaluronic acid gel formulated using Croma’s MACRO Core Technology to create a stable 3D HA matrix with predefined viscoelastic properties, high HA content, consistent gel distribution, and predictable injection force and swelling profile, aiming to provide natural-looking, durable midface volume augmentation with high patient satisfaction and a favorable safety profile across diverse skin types.

Brand names: Saypha CHICObagi saypha ChIQ
Other names: Saypha ChIQObagi saypha CHIC

Beyond the preview

Go deeper on Saypha CHIC.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Saypha CHIC.

Explore the full profile